Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
RESEARCH TOOLSreports
Total Valuation
Basilea Pharmaceutica has a market cap or net worth of CHF497.01M. The enterprise value is CHF560.54M.
Market CapCHF497.01M
Enterprise ValueCHF560.54M
Share Statistics
Basilea Pharmaceutica has 13.17M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13.17M
Owned by Insiders
Owned by Instutions0.11%
Financial Efficiency
Basilea Pharmaceutica’s return on equity (ROE) is 0.96 and return on invested capital (ROIC) is 36.76%.
Return on Equity (ROE)95.80%
Return on Assets (ROA)30.10%
Return on Invested Capital (ROIC)36.76%
Return on Capital Employed (ROCE)28.83%
Revenue Per EmployeeCHF1,271,603.659
Profits Per EmployeeCHF473,128.049
Employee Count164
Asset Turnover0.81
Inventory Turnover3.66
Valuation Ratios
The current PE Ratio of Basilea Pharmaceutica is 7.10. Basilea Pharmaceutica’s PEG ratio is 0.01.
PE Ratio7.10
PS Ratio2.64
PB Ratio6.80
Price to Fair Value6.80
Price to FCF7.58
Price to Operating Cash Flow7.41
PEG Ratio0.01
Income Statement
In the last 12 months, Basilea Pharmaceutica had revenue of CHF208.54M and earned CHF77.59M in profits. Earnings per share was CHF5.92.
RevenueCHF208.54M
Gross ProfitCHF126.32M
Operating IncomeCHF61.18M
Pretax IncomeCHF60.26M
Net IncomeCHF77.59M
EBITDA63.13M
Earnings Per Share (EPS)5.92
Cash Flow
In the last 12 months, operating cash flow was CHF74.36M and capital expenditures -CHF1.71M, giving a free cash flow of CHF72.65M billion.
Operating Cash FlowCHF74.36M
Free Cash FlowCHF72.65M
Free Cash Flow per ShareCHF5.52
Dividends & Yields
Basilea Pharmaceutica pays an annual dividend of CHF5.00, resulting in a dividend yield of
Dividend Per ShareCHF5.00
Dividend Yield
Payout Ratio
Free Cash Flow Yield13.19%
Earnings Yield14.09%
Stock Price Statistics
Beta0.97
52-Week Price Change0.98%
50-Day Moving Average44.37
200-Day Moving Average42.88
Relative Strength Index (RSI)39.87
Average Volume (3m)47.80K
Important Dates
Basilea Pharmaceutica upcoming earnings date is Aug 19, 2025, TBA.
Last Earnings DateFeb 18, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend DateApr 11, 2013
Financial Position
Basilea Pharmaceutica as a current ratio of 4.85, with Debt / Equity ratio of 1.38
Current Ratio4.85
Quick Ratio4.16
Debt to Market Cap0.17
Net Debt to EBITDA-0.14
Interest Coverage Ratio14.08
Taxes
In the past 12 months, Basilea Pharmaceutica has paid -CHF9.49M in taxes.
Income Tax-CHF9.49M
Effective Tax Rate-28.76%
Enterprise Valuation
Basilea Pharmaceutica EV to EBITDA ratio is 8.58, with an EV/FCF ratio of 7.46.
EV to Sales2.60
EV to EBITDA8.58
EV to Free Cash Flow7.46
EV to Operating Cash Flow7.29
Balance Sheet
Basilea Pharmaceutica has CHF120.71M in cash and marketable securities with CHF111.67M in debt, giving a net cash position of -CHF9.04M billion.
Cash & Marketable SecuritiesCHF120.71M
Total DebtCHF111.67M
Net Cash-CHF9.04M
Net Cash Per Share-CHF0.69
Tangible Book Value Per ShareCHF6.05
Margins
Gross margin is 44.46%, with operating margin of 29.34%, and net profit margin of 37.21%.
Gross Margin44.46%
Operating Margin29.34%
Pretax Margin28.90%
Net Profit Margin37.21%
EBITDA Margin30.27%
EBIT Margin29.59%
Analyst Forecast
The average price target for Basilea Pharmaceutica is CHF84.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF84.50
Price Target Upside104.60%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast